AbbVie to record $3.5B impairment charge for Cerevel drug

AbbVie (NYSE:ABBV) said it expects to record an impairment charge of approximately $3.5B related to the drug emraclidine, which it acquired through its acquisition of Cerevel Therapeutics last year.

The drugmaker disclosed in November that two Phase 2 studies of